These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9796889

  • 1. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 2. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G.
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [Abstract] [Full Text] [Related]

  • 3. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD.
    Am J Cardiol; 2005 Nov 01; 96(9):1266-72. PubMed ID: 16253595
    [Abstract] [Full Text] [Related]

  • 4. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct 01; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 5. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
    Fasching P, Rohac M, Liener K, Schneider B, Nowotny P, Waldhäusl W.
    Horm Metab Res; 1996 May 01; 28(5):230-6. PubMed ID: 8738112
    [Abstract] [Full Text] [Related]

  • 6. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 01; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 7. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
    Bröijersén A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P.
    Thromb Haemost; 1996 Aug 01; 76(2):171-6. PubMed ID: 8865525
    [Abstract] [Full Text] [Related]

  • 8. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.
    Circulation; 2006 Mar 28; 113(12):1556-63. PubMed ID: 16534013
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Mar 28; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC.
    Am J Kidney Dis; 2004 Nov 28; 44(5):832-9. PubMed ID: 15492949
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in Type II diabetes: effects of alpha-tocopherol supplementation.
    Sampson MJ, Astley S, Richardson T, Willis G, Davies IR, Hughes DA, Southon S.
    Clin Sci (Lond); 2001 Sep 28; 101(3):235-41. PubMed ID: 11524040
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec 28; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 19. Dyslipidaemia and coagulation defects of insulin resistance.
    Frohlich J, Steiner G.
    Int J Clin Pract Suppl; 2000 Oct 28; (113):14-22. PubMed ID: 11965826
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.